Evidence map›Paper›PMID 31011206›Full record

Trial reportNature medicine2019

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.

Jason K Sicklick, Shumei Kato, Ryosuke Okamura, Maria Schwaederle, Michael E Hahn, Casey B Williams, Pradip De, Amy Krie, David E Piccioni, Vincent A Miller and 9 more

Registry-linked trialAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07346209 (STudy of Real-world Individualized Precision-oncology), which is not on this map. Cited by 413 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
413citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07346209 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

STudy of Real-world Individualized Precision-oncology

TypeinterventionalSponsorUniversity of California, San DiegoRan2026 to 2031Enrolled280ConditionsMetastatic Cancer, Unresectable CarcinomaArmsMolecularly matched therapy, Standard of care
3 · Its place in the literature

Who cites it

413 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Claudin 18.2 Targeting: A Pan-Cancer Perspective.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Review
  13. Article
  14. Article
  15. Causal graph neural networks for healthcare.Nature biomedical engineering · 2026
    Review
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Review

353 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Jason K SicklickDivision of Surgical Oncology, Department of Surgery, University of California, San Diego, La Jolla, CA, USA. jsicklick@ucsd.edu.ORCID http://orcid.org/0000-0003-4403-0271
Shumei KatoMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Ryosuke OkamuraMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-7352-8621
Maria SchwaederleMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Michael E HahnDepartment of Radiology, University of California, San Diego, La Jolla, CA, USA.
Casey B WilliamsAvera Cancer Institute, Sioux Falls, SD, USA.
Pradip DeAvera Cancer Institute, Sioux Falls, SD, USA.
Amy KrieAvera Cancer Institute, Sioux Falls, SD, USA.
David E PiccioniMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Vincent A MillerFoundation Medicine, Inc., Cambridge, MA, USA.
Jeffrey S RossFoundation Medicine, Inc., Cambridge, MA, USA.
Adam BensonScipher Medicine, Waltham, MA, USA.
Jennifer WebsterFoundation Medicine, Inc., Cambridge, MA, USA.
Philip J StephensGRAIL, Inc., Menlo Park, CA, USA.
J Jack LeeDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-5469-9214
Paul T FantaMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Scott M LippmanMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Brian Leyland-JonesAvera Cancer Institute, Sioux Falls, SD, USA.
Razelle KurzrockMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA. rkurzrock@ucsd.edu.ORCID http://orcid.org/0000-0003-4110-1214

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9M
Novel Allosteric Kinase Inhibitors Target Imatinib-Resistant GISTK08CA168999 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SICKLICK, JASON KEITH · 2014 to 2018
$888k
Defining the Germline Genomic Landscape of a Novel GIST Multi-tumor SyndromeR21CA192072 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SICKLICK, JASON KEITH · 2016 to 2017
$399k
NCI NIH HHS K08 CA168999NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA023100NCI NIH HHS R21 CA192072
6 · The paper itself

Abstract

Cancer treatments have evolved from indiscriminate cytotoxic agents to selective genome- and immune-targeted drugs that have transformed the outcomes of some malignancies

Indexed as

AdultAgedAged, 80 and overCombined Modality TherapyFemaleGene Expression ProfilingHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMolecular Targeted TherapyNeoplasmsPrecision MedicineProgression-Free SurvivalProspective StudiesYoung Adult

Identifiers

PMID31011206
PMCPMC6553618

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.